<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33021970</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2379-3708</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>21</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>JCI insight</Title><ISOAbbreviation>JCI Insight</ISOAbbreviation></Journal><ArticleTitle>Monoclonal full-length antibody against TAR DNA binding protein 43 reduces related proteinopathy in neurons.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e140420</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1172/jci.insight.140420</ELocationID><ELocationID EIdType="pii" ValidYN="Y">140420</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), 2 incurable neurodegenerative disorders, share the same pathological hallmark named TDP43 (TAR DNA binding protein 43) proteinopathy. This event is characterized by a consistent cytoplasmic mislocalization and aggregation of the protein TDP43, which loses its physiological properties, leading neurons to death. Antibody-based approaches are now emerging interventions in the field of neurodegenerative disorders. Here, we tested the target specificity, in vivo distribution, and therapeutic efficacy of a monoclonal full-length antibody, named E6, in TDP43-related conditions. We observed that the antibody recognizes specifically the cytoplasmic fraction of TDP43. We demonstrated its ability in targeting large neurons in the spinal cord of mice and in reducing TDP43 mislocalization and NF-&#x3ba;B activation. We also recognized the proteasome as well as the lysosome machineries as possible mechanisms used by the antibody to reduce TDP43 proteinopathy. To our knowledge, this is the first report showing the therapeutic efficacy and feasibility of a full-length antibody against TDP43 in reducing TDP43 proteinopathy in spinal neurons of an ALS/FTLD mouse model.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pozzi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Qu&#xe9;bec, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Codron</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR CNRS 6015, INSERM U1083, University of Angers, Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soucy</LastName><ForeName>Genevi&#xe8;ve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Qu&#xe9;bec, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renaud</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Qu&#xe9;bec, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordeau</LastName><ForeName>Pierre Junior</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Qu&#xe9;bec, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutta</LastName><ForeName>Kallol</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Qu&#xe9;bec, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bareil</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Qu&#xe9;bec, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Julien</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Qu&#xe9;bec, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neuroscience, University of Laval, Qu&#xe9;bec City, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ICT-171454</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCI Insight</MedlineTA><NlmUniqueID>101676073</NlmUniqueID><ISSNLinking>2379-3708</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Neuroscience</Keyword><Keyword MajorTopicYN="N">Therapeutics</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> JPJ and SP are owners of a patent US 15/532,909 titled &#x201c;TDP43-binding polypeptides useful for the treatment of neurodegenerative diseases.&#x201d; JPJ is chief scientific officer of Imstar Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>6</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33021970</ArticleId><ArticleId IdType="pmc">PMC7710295</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.140420</ArticleId><ArticleId IdType="pii">140420</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buratti E. Functional Significance of TDP-43 Mutations in Disease. Adv Genet. 2015;91:1&#x2013;53. doi: 10.1016/bs.adgen.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.adgen.2015.07.001</ArticleId><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Prim. 2017;3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem. 2016;138 Suppl 1:54&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">27306735</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388(10047):919&#x2013;931. doi: 10.1016/S0140-6736(16)00737-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00737-6</ArticleId><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T. Significance and limitation of the pathological classification of TDP-43 proteinopathy. Neuropathology. 2014;34(6):578&#x2013;588. doi: 10.1111/neup.12138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12138</ArticleId><ArticleId IdType="pubmed">25196969</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanazawa M, et al. Biochemical and histopathological alterations in TAR DNA-binding protein-43 after acute ischemic stroke in rats. J Neurochem. 2011;116(6):957&#x2013;965. doi: 10.1111/j.1471-4159.2010.06860.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06860.x</ArticleId><ArticleId IdType="pubmed">20557425</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci. 2010;30(2):639&#x2013;649. doi: 10.1523/JNEUROSCI.4988-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4988-09.2010</ArticleId><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Chen HJ, Shaw CE. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics. 2015;12(2):352&#x2013;363. doi: 10.1007/s13311-015-0338-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0338-x</ArticleId><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015;130(5):643&#x2013;660. doi: 10.1007/s00401-015-1460-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1460-x</ArticleId><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Freskg&#xe5;rd PO, Urich E. Antibody therapies in CNS diseases. Neuropharmacology. 2017;120:38&#x2013;55. doi: 10.1016/j.neuropharm.2016.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.03.014</ArticleId><ArticleId IdType="pubmed">26972827</ArticleId></ArticleIdList></Reference><Reference><Citation>Valera E, Spencer B, Masliah E. Immunotherapeutic Approaches Targeting Amyloid-&#x3b2;, &#x3b1;-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics. 2016;13(1):179&#x2013;189. doi: 10.1007/s13311-015-0397-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0397-z</ArticleId><ArticleId IdType="pmc">PMC4720672</ArticleId><ArticleId IdType="pubmed">26494242</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2007;104(7):2495&#x2013;2500. doi: 10.1073/pnas.0606201104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0606201104</ArticleId><ArticleId IdType="pmc">PMC1790867</ArticleId><ArticleId IdType="pubmed">17277077</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros-Louis F, Soucy G, Larivi&#xe8;re R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem. 2010;113(5):1188&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pubmed">20345765</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HN, et al. Targeting of monomer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis. J Neurosci. 2012;32(26):8791&#x2013;8799. doi: 10.1523/JNEUROSCI.5053-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5053-11.2012</ArticleId><ArticleId IdType="pmc">PMC6622344</ArticleId><ArticleId IdType="pubmed">22745481</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, et al. Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol Ther. 2014;22(3):498&#x2013;510. doi: 10.1038/mt.2013.239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.239</ArticleId><ArticleId IdType="pmc">PMC3944333</ArticleId><ArticleId IdType="pubmed">24394188</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkler C, O&#x2019;Neil AL, Slepian S, Qian F, Weinreb PH, Rubin LL. Aggregated SOD1 causes selective death of cultured human motor neurons. Sci Rep. 2018;8(1):16393. doi: 10.1038/s41598-018-34759-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-34759-z</ArticleId><ArticleId IdType="pmc">PMC6219543</ArticleId><ArticleId IdType="pubmed">30401824</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadge GD, Kay BK, Drigotas C, Roos RP. Single chain variable fragment antibodies directed against SOD1 ameliorate disease in mutant SOD1 transgenic mice. Neurobiol Dis. 2019;121:131&#x2013;137. doi: 10.1016/j.nbd.2018.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.08.021</ArticleId><ArticleId IdType="pubmed">30176351</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadge GD, Pavlovic JD, Koduvayur SP, Kay BK, Roos RP. Single chain variable fragment antibodies block aggregation and toxicity induced by familial ALS-linked mutant forms of SOD1. Neurobiol Dis. 2013;56:74&#x2013;78. doi: 10.1016/j.nbd.2013.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.04.007</ArticleId><ArticleId IdType="pmc">PMC3725968</ArticleId><ArticleId IdType="pubmed">23607939</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi S, et al. Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology. J Clin Invest. 2019;129(4):1581&#x2013;1595. doi: 10.1172/JCI123931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI123931</ArticleId><ArticleId IdType="pmc">PMC6436898</ArticleId><ArticleId IdType="pubmed">30667370</ArticleId></ArticleIdList></Reference><Reference><Citation>Che MX, Jiang YJ, Xie YY, Jiang LL, Hu HY. Aggregation of the 35-kDa fragment of TDP-43 causes formation of cytoplasmic inclusions and alteration of RNA processing. FASEB J. 2011;25(7):2344&#x2013;2353. doi: 10.1096/fj.10-174482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.10-174482</ArticleId><ArticleId IdType="pubmed">21450909</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134(Pt 9):2610&#x2013;2626.</Citation><ArticleIdList><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Sato T, Bamba H, Hisa Y, Tooyama I. Synergistic effect between proteasome and autophagosome in the clearance of polyubiquitinated TDP-43. J Neurosci Res. 2010;88(4):784&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">19798749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta K, Patel P, Rahimian R, Phaneuf D, Julien JP. Withania somnifera Reverses Transactive Response DNA Binding Protein 43 Proteinopathy in a Mouse Model of Amyotrophic Lateral Sclerosis/Frontotemporal Lobar Degeneration. Neurotherapeutics. 2017;14(2):447&#x2013;462. doi: 10.1007/s13311-016-0499-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0499-2</ArticleId><ArticleId IdType="pmc">PMC5398980</ArticleId><ArticleId IdType="pubmed">27928708</ArticleId></ArticleIdList></Reference><Reference><Citation>Clift D, et al. A Method for the Acute and Rapid Degradation of Endogenous Proteins. Cell. 2017;171(7):1692&#x2013;1706.e18. doi: 10.1016/j.cell.2017.10.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.033</ArticleId><ArticleId IdType="pmc">PMC5733393</ArticleId><ArticleId IdType="pubmed">29153837</ArticleId></ArticleIdList></Reference><Reference><Citation>Clift D, So C, McEwan WA, James LC, Schuh M. Acute and rapid degradation of endogenous proteins by Trim-Away. Nat Protoc. 2018;13(10):2149&#x2013;2175. doi: 10.1038/s41596-018-0028-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-018-0028-3</ArticleId><ArticleId IdType="pubmed">30250286</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L, et al. Antibody Therapy Targeting RAN Proteins Rescues C9 ALS/FTD Phenotypes in C9orf72 Mouse Model. Neuron. 2020;105(4):645&#x2013;662.e11. doi: 10.1016/j.neuron.2019.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.11.007</ArticleId><ArticleId IdType="pmc">PMC7391607</ArticleId><ArticleId IdType="pubmed">31831332</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Congdon EE, Sigurdsson EM. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem. 2013;288(46):33081&#x2013;33095. doi: 10.1074/jbc.M113.494922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.494922</ArticleId><ArticleId IdType="pmc">PMC3829157</ArticleId><ArticleId IdType="pubmed">24089520</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar NN, Pizzo ME, Nehra G, Wilken-Resman B, Boroumand S, Thorne RG. Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. Bioconjug Chem. 2018;29(12):3937&#x2013;3966. doi: 10.1021/acs.bioconjchem.8b00548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.bioconjchem.8b00548</ArticleId><ArticleId IdType="pmc">PMC7234797</ArticleId><ArticleId IdType="pubmed">30265523</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor &#x3ba;B-mediated pathogenic pathways. J Exp Med. 2011;208(12):2429&#x2013;2447. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, et al. HDAC-mediated deacetylation of NF-&#x3ba;B is critical for Schwann cell myelination. Nat Neurosci. 2011;14(4):437&#x2013;441. doi: 10.1038/nn.2780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2780</ArticleId><ArticleId IdType="pmc">PMC3074381</ArticleId><ArticleId IdType="pubmed">21423191</ArticleId></ArticleIdList></Reference><Reference><Citation>Velagapudi R, El-Bakoush A, Olajide OA. Activation of Nrf2 Pathway Contributes to Neuroprotection by the Dietary Flavonoid Tiliroside. Mol Neurobiol. 2018;55(10):8103&#x2013;8123. doi: 10.1007/s12035-018-0975-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0975-2</ArticleId><ArticleId IdType="pmc">PMC6132780</ArticleId><ArticleId IdType="pubmed">29508282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bros-Facer V, et al. Treatment with an antibody directed against Nogo-A delays disease progression in the SOD1G93A mouse model of Amyotrophic lateral sclerosis. Hum Mol Genet. 2014;23(16):4187&#x2013;4200. doi: 10.1093/hmg/ddu136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu136</ArticleId><ArticleId IdType="pubmed">24667415</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, et al. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial. PLoS One. 2014;9(5):e97803. doi: 10.1371/journal.pone.0097803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0097803</ArticleId><ArticleId IdType="pmc">PMC4026380</ArticleId><ArticleId IdType="pubmed">24841795</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravel M, et al. IL-10 Controls Early Microglial Phenotypes and Disease Onset in ALS Caused by Misfolded Superoxide Dismutase 1. J Neurosci. 2016;36(3):1031&#x2013;1048. doi: 10.1523/JNEUROSCI.0854-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0854-15.2016</ArticleId><ArticleId IdType="pmc">PMC6601999</ArticleId><ArticleId IdType="pubmed">26791230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, et al. Antibodies inhibit transmission and aggregation of C9orf72 poly-GA dipeptide repeat proteins. EMBO Mol Med. 2017;9(5):687&#x2013;702. doi: 10.15252/emmm.201607054.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201607054</ArticleId><ArticleId IdType="pmc">PMC5412769</ArticleId><ArticleId IdType="pubmed">28351931</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Gu J, Sait HB, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fc&#x3b3; receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013;288(49):35452&#x2013;35465. doi: 10.1074/jbc.M113.491001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.491001</ArticleId><ArticleId IdType="pmc">PMC3853292</ArticleId><ArticleId IdType="pubmed">24163366</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan WA, et al. Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc Natl Acad Sci U S A. 2017;114(3):574&#x2013;579. doi: 10.1073/pnas.1607215114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1607215114</ArticleId><ArticleId IdType="pmc">PMC5255578</ArticleId><ArticleId IdType="pubmed">28049840</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Dormann D. TDP-43 and FUS en route from the nucleus to the cytoplasm. FEBS Lett. 2017;591(11):1489&#x2013;1507. doi: 10.1002/1873-3468.12646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.12646</ArticleId><ArticleId IdType="pubmed">28380257</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Wang L, Huntley ML, Perry G, Wang X. Pathomechanisms of TDP-43 in neurodegeneration. J Neurochem. 2018;146(1):7&#x2013;20. doi: 10.1111/jnc.14327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14327</ArticleId><ArticleId IdType="pmc">PMC6110993</ArticleId><ArticleId IdType="pubmed">29486049</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YJ, et al. DNA Binding Induces a Nanomechanical Switch in the RRM1 Domain of TDP-43. J Phys Chem Lett. 2018;9(14):3800&#x2013;3807. doi: 10.1021/acs.jpclett.8b01494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpclett.8b01494</ArticleId><ArticleId IdType="pubmed">29924934</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan WA, Mallery DL, Rhodes DA, Trowsdale J, James LC. Intracellular antibody-mediated immunity and the role of TRIM21. Bioessays. 2011;33(11):803&#x2013;809. doi: 10.1002/bies.201100093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.201100093</ArticleId><ArticleId IdType="pubmed">22006823</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther. 2008;7(8):2517&#x2013;2527. doi: 10.1158/1535-7163.MCT-08-0201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-08-0201</ArticleId><ArticleId IdType="pubmed">18723496</ArticleId></ArticleIdList></Reference><Reference><Citation>Peress NS, Fleit HB, Perillo E, Kuljis R, Pezzullo C. Identification of Fc gamma RI, II and III on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer&#x2019;s disease. J Neuroimmunol. 1993;48(1):71&#x2013;79. doi: 10.1016/0165-5728(93)90060-C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(93)90060-C</ArticleId><ArticleId IdType="pubmed">8227309</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller KJ, et al. Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat Neurosci. 2018;21(3):329&#x2013;340. doi: 10.1038/s41593-018-0083-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0083-7</ArticleId><ArticleId IdType="pmc">PMC5857237</ArticleId><ArticleId IdType="pubmed">29463850</ArticleId></ArticleIdList></Reference><Reference><Citation>Pincetic A, et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol. 2014;15(8):707&#x2013;716. doi: 10.1038/ni.2939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2939</ArticleId><ArticleId IdType="pmc">PMC7430760</ArticleId><ArticleId IdType="pubmed">25045879</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. Signaling by Antibodies: Recent Progress. Annu Rev Immunol. 2017;35:285&#x2013;311. doi: 10.1146/annurev-immunol-051116-052433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-051116-052433</ArticleId><ArticleId IdType="pmc">PMC5613280</ArticleId><ArticleId IdType="pubmed">28446061</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, et al. HO-1 induction in motor cortex and intestinal dysfunction in TDP-43 A315T transgenic mice. Brain Res. 2012;1460:88&#x2013;95. doi: 10.1016/j.brainres.2012.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.04.003</ArticleId><ArticleId IdType="pubmed">22578468</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili MA, Panahi M, Yadav S, Hennings L, Kiaei M. Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. Int J Exp Pathol. 2013;94(1):56&#x2013;64. doi: 10.1111/iep.12006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iep.12006</ArticleId><ArticleId IdType="pmc">PMC3575874</ArticleId><ArticleId IdType="pubmed">23317354</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdewyn S, Cirillo C, Van Den Bosch L, Robberecht W, Vanden Berghe P, Van Damme P. Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice. Mol Neurodegener. 2014;9:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4088917</ArticleId><ArticleId IdType="pubmed">24938805</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G, et al. Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations. Acta Neuropathol. 2011;121(5):611&#x2013;622. doi: 10.1007/s00401-010-0786-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0786-7</ArticleId><ArticleId IdType="pubmed">21120508</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda C, et al. Effect of nitric oxide on lymphocytes from sporadic amyotrophic lateral sclerosis patients: toxic or protective role? Neurol Sci. 2006;27(5):312&#x2013;316. doi: 10.1007/s10072-006-0702-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-006-0702-z</ArticleId><ArticleId IdType="pubmed">17122939</ArticleId></ArticleIdList></Reference><Reference><Citation>Cova E, et al. Modified expression of Bcl-2 and SOD1 proteins in lymphocytes from sporadic ALS patients. Neurosci Lett. 2006;399(3):186&#x2013;190. doi: 10.1016/j.neulet.2006.01.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2006.01.057</ArticleId><ArticleId IdType="pubmed">16495003</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134(Pt 5):1293&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, et al. Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model. JAMA Neurol. 2018;75(6):681&#x2013;689. doi: 10.1001/jamaneurol.2018.0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar NN, et al. Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery. J Control Release. 2018;286:467&#x2013;484. doi: 10.1016/j.jconrel.2018.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2018.08.006</ArticleId><ArticleId IdType="pmc">PMC7234798</ArticleId><ArticleId IdType="pubmed">30081144</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasetto L, et al. Targeting Extracellular Cyclophilin A Reduces Neuroinflammation and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis. J Neurosci. 2017;37(6):1413&#x2013;1427. doi: 10.1523/JNEUROSCI.2462-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2462-16.2016</ArticleId><ArticleId IdType="pmc">PMC6705677</ArticleId><ArticleId IdType="pubmed">28011744</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, et al. Nitroproteomics of peripheral blood mononuclear cells from patients and a rat model of ALS. Antioxid Redox Signal. 2009;11(7):1559&#x2013;1567. doi: 10.1089/ars.2009.2548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2009.2548</ArticleId><ArticleId IdType="pubmed">19290778</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One. 2011;6(10):e25545. doi: 10.1371/journal.pone.0025545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025545</ArticleId><ArticleId IdType="pmc">PMC3187793</ArticleId><ArticleId IdType="pubmed">21998667</ArticleId></ArticleIdList></Reference><Reference><Citation>Codron P, et al. Primary fibroblasts derived from sporadic amyotrophic lateral sclerosis patients do not show ALS cytological lesions. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5-6):446&#x2013;456. doi: 10.1080/21678421.2018.1431787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1431787</ArticleId><ArticleId IdType="pubmed">29382228</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012;122(9):3063&#x2013;3087. doi: 10.1172/JCI62636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI62636</ArticleId><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>